NEU-411, an investigational treatment, for people with LRRK2-driven Parkinson’s disease

The NEULARK Trial, sponsored by Neuron23, is investigating NEU-411, a once-daily oral medication, to evaluate its potential to slow the progression of Parkinson’s disease in individuals with LRRK2-driven Parkinson’s. This specific form of Parkinson’s disease is associated with an overactive LRRK2 gene, which can be identified through a simple blood test. The trial is currently recruiting participants aged 50 to 80 who have been diagnosed with Parkinson’s disease and have not yet started dopamine-based treatments. NEU-411 is designed to inhibit the overactive LRRK2 pathway, aiming to slow symptom progression and improve quality of life for individuals with Parkinson’s. The study will assess both the safety and effectiveness of the drug. Participants will receive close monitoring and care from a team of specialists, as well as the opportunity to contribute to important medical research. While the investigational treatment may offer potential benefits, the study team will provide detailed information about any associated risks to help participants make informed decisions. LRRK2-driven Parkinson’s disease results from excessive activity in the LRRK2 pathway, leading to brain damage and the onset of Parkinson’s symptoms. This condition can occur even in individuals without a family history of Parkinson’s disease. Testing for LRRK2 involvement is a key step in determining eligibility for the NEULARK trial and advancing personalized approaches to Parkinson’s treatment.